What is the sentiment of this news? Please choose an answer from {strong negative/moderately negative/mildly negative/neutral/mildly positive/moderately positive/strong positive}.

Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.
moderately positive